Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.19
PDLI's Cash-to-Debt is ranked lower than
71% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. PDLI: 2.19 )
Ranked among companies with meaningful Cash-to-Debt only.
PDLI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.25  Med: 2.04 Max: No Debt
Current: 2.19
0.25
No Debt
Equity-to-Asset 0.68
PDLI's Equity-to-Asset is ranked lower than
51% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PDLI: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
PDLI' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.85  Med: 0.68 Max: 0.97
Current: 0.68
-1.85
0.97
Debt-to-Equity 0.29
PDLI's Debt-to-Equity is ranked lower than
52% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. PDLI: 0.29 )
Ranked among companies with meaningful Debt-to-Equity only.
PDLI' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.55  Med: 0.29 Max: 3.48
Current: 0.29
-4.55
3.48
Debt-to-EBITDA 1.05
PDLI's Debt-to-EBITDA is ranked higher than
61% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. PDLI: 1.05 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PDLI' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.46  Med: 1.12 Max: 2.65
Current: 1.05
0.46
2.65
Interest Coverage 8.72
PDLI's Interest Coverage is ranked lower than
87% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PDLI: 8.72 )
Ranked among companies with meaningful Interest Coverage only.
PDLI' s Interest Coverage Range Over the Past 10 Years
Min: 4.85  Med: 12.37 Max: 19.15
Current: 8.72
4.85
19.15
Piotroski F-Score: 7
Altman Z-Score: 2.96
Beneish M-Score: -2.44
WACC vs ROIC
4.76%
17.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 58.34
PDLI's Operating Margin % is ranked higher than
96% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. PDLI: 58.34 )
Ranked among companies with meaningful Operating Margin % only.
PDLI' s Operating Margin % Range Over the Past 10 Years
Min: 58.34  Med: 93.2 Max: 94.93
Current: 58.34
58.34
94.93
Net Margin % 36.63
PDLI's Net Margin % is ranked higher than
91% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. PDLI: 36.63 )
Ranked among companies with meaningful Net Margin % only.
PDLI' s Net Margin % Range Over the Past 10 Years
Min: 23.25  Med: 55.8 Max: 60.49
Current: 36.63
23.25
60.49
ROE % 13.85
PDLI's ROE % is ranked higher than
86% of the 969 Companies
in the Global Biotechnology industry.

( Industry Median: -40.23 vs. PDLI: 13.85 )
Ranked among companies with meaningful ROE % only.
PDLI' s ROE % Range Over the Past 10 Years
Min: 8.79  Med: 72.89 Max: 1166.18
Current: 13.85
8.79
1166.18
ROA % 8.90
PDLI's ROA % is ranked higher than
86% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. PDLI: 8.90 )
Ranked among companies with meaningful ROA % only.
PDLI' s ROA % Range Over the Past 10 Years
Min: 5.71  Med: 38.25 Max: 77.05
Current: 8.9
5.71
77.05
ROC (Joel Greenblatt) % 4054.74
PDLI's ROC (Joel Greenblatt) % is ranked higher than
98% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. PDLI: 4054.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PDLI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 98.44  Med: 82080.42 Max: 1198273.12
Current: 4054.74
98.44
1198273.12
3-Year Revenue Growth Rate -14.40
PDLI's 3-Year Revenue Growth Rate is ranked lower than
72% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. PDLI: -14.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PDLI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -22  Med: 13.4 Max: 65.5
Current: -14.4
-22
65.5
3-Year EBITDA Growth Rate -22.00
PDLI's 3-Year EBITDA Growth Rate is ranked lower than
83% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. PDLI: -22.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PDLI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -15 Max: 202.9
Current: -22
0
202.9
3-Year EPS without NRI Growth Rate -27.50
PDLI's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PDLI: -27.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PDLI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -43.2 Max: 89.5
Current: -27.5
0
89.5
GuruFocus has detected 4 Warning Signs with PDL BioPharma Inc PDLI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PDLI's 30-Y Financials

Financials (Next Earnings Date: 2018-05-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

PDLI Guru Trades in Q1 2017

Charles Brandes 58,578 sh (New)
First Eagle Investment 2,800 sh (unchged)
Joel Greenblatt Sold Out
Jim Simons 12,036,754 sh (-6.52%)
Paul Tudor Jones 213,284 sh (-27.06%)
Barrow, Hanley, Mewhinney & Strauss 25,387 sh (-91.47%)
Jeremy Grantham 63,997 sh (-94.02%)
» More
Q2 2017

PDLI Guru Trades in Q2 2017

Charles Brandes 1,107,310 sh (+1790.32%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 25,387 sh (unchged)
Paul Tudor Jones Sold Out
Jeremy Grantham Sold Out
Jim Simons 10,704,400 sh (-11.07%)
» More
Q3 2017

PDLI Guru Trades in Q3 2017

Chuck Royce 4,302 sh (New)
Jim Simons 11,131,786 sh (+3.99%)
Charles Brandes 1,112,679 sh (+0.48%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 23,201 sh (-8.61%)
» More
Q4 2017

PDLI Guru Trades in Q4 2017

Pioneer Investments 20,000 sh (New)
Chuck Royce 5,015 sh (+16.57%)
First Eagle Investment 2,800 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Charles Brandes 1,100,518 sh (-1.09%)
Jim Simons 10,284,454 sh (-7.61%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:PDLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2017-12-31 Reduce -1.09%$2.74 - $3.51 $ 2.90-6%1,100,518
Barrow, Hanley, Mewhinney & Strauss 2017-12-31 Sold Out $2.74 - $3.51 $ 2.90-6%0
Charles Brandes 2017-09-30 Add 0.48%$2.17 - $3.4 $ 2.905%1,112,679
Barrow, Hanley, Mewhinney & Strauss 2017-09-30 Reduce -8.61%$2.17 - $3.4 $ 2.905%23,201
Charles Brandes 2017-06-30 Add 1790.32%0.05%$2.02 - $2.59 $ 2.9026%1,107,310
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:CYTK, SZSE:002566, XKRX:087010, XKRX:214450, XMCE:PHM, SZSE:002873, TSX:AUP, NAS:STML, OSTO:KARO, XKRX:182400, NAS:INO, NAS:PTGX, NAS:SIGA, NAS:INSY, NAS:GTXI, SHSE:603538, NAS:PRTK, SZSE:300653, NAS:KALA, OCSE:ZEAL » details
Traded in other countries:PDL.Germany,
Headquarter Location:USA
PDL BioPharma Inc is engaged in the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing value of its patent.

PDL BioPharma Inc discovers and develops humanized monoclonal antibodies and receives royalties from nine marketed products licensed under PDL patents. The ESP Pharma acquisition brought marketed products to PDL in 2005, but because of a lack of strategic fit, PDL sold its commercial assets in early 2008. After paying a special dividend to shareholders, PDL has spun off its drug-discovery and -development business and plans to continue distributing royalty-based income to shareholders.

Top Ranked Articles about PDL BioPharma Inc

PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant Concerns
PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference
PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018
Neos Therapeutics Reiterates Confidence in Strategic Plan and Value Creation Opportunities
PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos
PDL BioPharma to Present at Two Upcoming Investor Conferences
9 Positions Charles Brandes Increased in the Past 2 Quarters Avon, Infosys among guru's investments
Brandes Investment leader Charles Brandes (Trades, Portfolio) is considered one of the most important value investors today. He follows the Benjamin Graham school of value investing. In both the second and third quarters, he invested in the following stocks: Read more...
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth

Ratios

vs
industry
vs
history
PE Ratio 4.04
PDLI's PE Ratio is ranked higher than
90% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.83 vs. PDLI: 4.04 )
Ranked among companies with meaningful PE Ratio only.
PDLI' s PE Ratio Range Over the Past 10 Years
Min: 1.46  Med: 5.3 Max: 26.56
Current: 4.04
1.46
26.56
Forward PE Ratio 33.11
PDLI's Forward PE Ratio is ranked lower than
61% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 24.45 vs. PDLI: 33.11 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 4.04
PDLI's PE Ratio without NRI is ranked higher than
91% of the 255 Companies
in the Global Biotechnology industry.

( Industry Median: 30.45 vs. PDLI: 4.04 )
Ranked among companies with meaningful PE Ratio without NRI only.
PDLI' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.46  Med: 5.01 Max: 26.56
Current: 4.04
1.46
26.56
PB Ratio 0.52
PDLI's PB Ratio is ranked higher than
97% of the 954 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. PDLI: 0.52 )
Ranked among companies with meaningful PB Ratio only.
PDLI' s PB Ratio Range Over the Past 10 Years
Min: 0.43  Med: 2.32 Max: 38.99
Current: 0.52
0.43
38.99
PS Ratio 1.48
PDLI's PS Ratio is ranked higher than
91% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PDLI: 1.48 )
Ranked among companies with meaningful PS Ratio only.
PDLI' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 2.9 Max: 15.85
Current: 1.48
0.87
15.85
Price-to-Free-Cash-Flow 12.36
PDLI's Price-to-Free-Cash-Flow is ranked higher than
91% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 33.20 vs. PDLI: 12.36 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PDLI' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.26 Max: 13.46
Current: 12.36
1.51
13.46
Price-to-Operating-Cash-Flow 11.93
PDLI's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 30.32 vs. PDLI: 11.93 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PDLI' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.51  Med: 5.72 Max: 55.87
Current: 11.93
1.51
55.87
EV-to-EBIT 0.78
PDLI's EV-to-EBIT is ranked higher than
92% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. PDLI: 0.78 )
Ranked among companies with meaningful EV-to-EBIT only.
PDLI' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.4  Med: 3.4 Max: 14.8
Current: 0.78
0.4
14.8
EV-to-EBITDA 0.66
PDLI's EV-to-EBITDA is ranked higher than
93% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. PDLI: 0.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
PDLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.3  Med: 3.3 Max: 10.9
Current: 0.66
0.3
10.9
EV-to-Revenue 0.51
PDLI's EV-to-Revenue is ranked higher than
98% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. PDLI: 0.51 )
Ranked among companies with meaningful EV-to-Revenue only.
PDLI' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.3  Med: 3.3 Max: 15.7
Current: 0.51
0.3
15.7
Shiller PE Ratio 2.44
PDLI's Shiller PE Ratio is ranked higher than
92% of the 79 Companies
in the Global Biotechnology industry.

( Industry Median: 44.16 vs. PDLI: 2.44 )
Ranked among companies with meaningful Shiller PE Ratio only.
PDLI' s Shiller PE Ratio Range Over the Past 10 Years
Min: 1.78  Med: 5.06 Max: 209.25
Current: 2.44
1.78
209.25
Current Ratio 3.32
PDLI's Current Ratio is ranked lower than
60% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. PDLI: 3.32 )
Ranked among companies with meaningful Current Ratio only.
PDLI' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 9.88 Max: 57.61
Current: 3.32
0.26
57.61
Quick Ratio 3.27
PDLI's Quick Ratio is ranked lower than
57% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. PDLI: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
PDLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 9.88 Max: 57.61
Current: 3.27
0.26
57.61
Days Inventory 93.78
PDLI's Days Inventory is ranked lower than
54% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. PDLI: 93.78 )
Ranked among companies with meaningful Days Inventory only.
PDLI' s Days Inventory Range Over the Past 10 Years
Min: 71.9  Med: 100.69 Max: 129.48
Current: 93.78
71.9
129.48
Days Sales Outstanding 37.65
PDLI's Days Sales Outstanding is ranked higher than
83% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. PDLI: 37.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
PDLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.21  Med: 0.6 Max: 68.46
Current: 37.65
0.21
68.46
Days Payable 236.48
PDLI's Days Payable is ranked higher than
85% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. PDLI: 236.48 )
Ranked among companies with meaningful Days Payable only.
PDLI' s Days Payable Range Over the Past 10 Years
Min: 236.48  Med: 433.23 Max: 629.97
Current: 236.48
236.48
629.97

Buy Back

vs
industry
vs
history
3-Year Dividend Growth Rate -100.00
PDLI's 3-Year Dividend Growth Rate is ranked lower than
83% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. PDLI: -100.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PDLI' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -45
Current: -100
5-Year Yield-on-Cost % 0.58
PDLI's 5-Year Yield-on-Cost % is ranked lower than
79% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. PDLI: 0.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PDLI' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.54  Med: 2.19 Max: 5.71
Current: 0.58
0.54
5.71
3-Year Average Share Buyback Ratio 1.60
PDLI's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. PDLI: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PDLI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -5.5 Max: 1.6
Current: 1.6
-7.9
1.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.33
PDLI's Price-to-Net-Cash is ranked higher than
75% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 8.85 vs. PDLI: 3.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PDLI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.24  Med: 16.12 Max: 205.5
Current: 3.33
1.24
205.5
Price-to-Net-Current-Asset-Value 1.84
PDLI's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. PDLI: 1.84 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PDLI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.22  Med: 5.73 Max: 41.53
Current: 1.84
1.22
41.53
Price-to-Tangible-Book 1.59
PDLI's Price-to-Tangible-Book is ranked higher than
87% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. PDLI: 1.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PDLI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.99  Med: 3.09 Max: 31.88
Current: 1.59
0.99
31.88
Price-to-Intrinsic-Value-Projected-FCF 0.17
PDLI's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
98% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 3.54 vs. PDLI: 0.17 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PDLI' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.13  Med: 1.29 Max: 20.91
Current: 0.17
0.13
20.91
Price-to-Median-PS-Value 0.52
PDLI's Price-to-Median-PS-Value is ranked higher than
81% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. PDLI: 0.52 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PDLI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 3.94 Max: 22.55
Current: 0.52
0.36
22.55
Price-to-Graham-Number 0.53
PDLI's Price-to-Graham-Number is ranked higher than
91% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 2.76 vs. PDLI: 0.53 )
Ranked among companies with meaningful Price-to-Graham-Number only.
PDLI' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.39  Med: 1.14 Max: 26.4
Current: 0.53
0.39
26.4
Earnings Yield (Greenblatt) % 129.87
PDLI's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. PDLI: 129.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PDLI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.8  Med: 29.6 Max: 265.1
Current: 129.87
6.8
265.1
Forward Rate of Return (Yacktman) % 22.92
PDLI's Forward Rate of Return (Yacktman) % is ranked higher than
94% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 12.87 vs. PDLI: 22.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PDLI' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8.7  Med: 14.85 Max: 71.3
Current: 22.92
-8.7
71.3

More Statistics

Revenue (TTM) (Mil) $302.32
EPS (TTM) $ 0.72
Beta0.30
Volatility50.70%
52-Week Range $2.01 - 3.55
Shares Outstanding (Mil)153.81

Analyst Estimate

Dec18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 0.09
EPS without NRI ($) 0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}